collection
MENU ▼
Read by QxMD icon Read
search

Lnh llc

shared collection
3 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28608720/diagnostic-algorithm-of-common-mature-b-cell-lymphomas-by-immunohistochemistry
#1
REVIEW
Huan-You Wang, Youli Zu
CONTEXT: - Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity. OBJECTIVES: - To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells...
September 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28367662/adverse-drug-reactions-after-intravenous-rituximab-infusion-are-more-common-in-hematologic-malignancies-than-in-autoimmune-disorders-and-can-be-predicted-by-the-combination-of-few-clinical-and-laboratory-parameters-results-from-a-retrospective-multicenter-study
#2
Giovanni D'Arena, Vittorio Simeon, Luca Laurenti, Michele Cimminiello, Idanna Innocenti, Michele Gilio, Angela Padula, Maria Luigia Vigliotti, Sonya De Lorenzo, Giacomo Loseto, Anna Passarelli, Matteo Nicola Dario Di Minno, Marco Tucci, Vincenzo De Feo, Fiorella D'Auria, Francesco Silvestris, Giovanni Di Minno, Pellegrino Musto
Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8-135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25-35.9%), than in autoimmune diseases (9...
November 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27701070/esmo-consensus-conference-on-malignant-lymphoma-general-perspectives-and-recommendations-for-prognostic-tools-in-mature-b-cell-lymphomas-and-chronic-lymphocytic-leukaemia
#3
M Ladetto, C Buske, M Hutchings, M Dreyling, G Gaidano, S Le Gouill, S Luminari, C Pott, A Zamò, E Zucca
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group...
December 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"